| Company Structure |
| |
 |
Jonathan Louw
Chief Executive Officer
MB.ChB; MBA
Dr. Jonathan Louw joined Adcock in 2001 as New Business Development director, overseeing geographic expansion and spearheading acquisitions such as the acquisition of the consumer business of Abbott Laboratories and the Parke-Med division of Pfizer. He took over the management of the pharmaceutical business in late 2002, restructuring the businessand integrating the acquisition of the Organonbusiness and VitaThion. He is currently the chief executive officer of Adcock, encompassing the Pharmaceuticals and Hospital Products divisions. He is currently the Vice President of the Pharmaceutical Industry Association of South Africa. |
| |
| |
 |
Andy Hall
Chief Financial Officer
CA (SA), B. Pharm
Andy Hall joined Adcock Ingram in October 2007 as the Chief Financial Officer of Adcock. He was previously the Chief Financial Officer of Enaleniand prior to that the partner in charge of health sciences at Ernst & Young where he was with the firm for 12 years. Prior to joining Ernst & Young he was involved in retail pharmacy for 2 years andin sales and marketing with Pfizer for 5 years. |
| |
| |
 |
Basadi Letsoalo
Human Resources Executive
Hons Psych; CLDP;MLPC
Basadifeela Letsoalo joined Adcock in January 2008. Pursuant to numerous career paths, she carved passionate interest in Retail banking, initially with Absa as head of HR Information Management and joined Standard Bank SA as head of transformation. She spent a short stint with Edcon Group as HR Strategist for special assignments.
|
| |
| |
 |
Bill Tweedie
Managing Executive—OTC & Pharmaceuticals
B ComptHonsCA (SA)
Bill Tweedie has held various financial positions in Adcock and Tiger Brands—including Group Financial Executive of Tiger Brands. He has been with Tiger Brands and Adcock for 10 years. Three years ago he joined Adcock in a general management role. He was the Financial Director of the Hospital Products division and managed National Renal Care. Prior to his appointment as Managing Executive –OTC and Pharmaceuticals, he was Managing Executive of the OTC division for 3.5 years.
|
| |
| |
 |
Kuben Pillay
Executive –Strategic Trade, ARVs & Tenders
BSc; NHD; PBL; MBA
Kuben Pillay graduated as an Industrial Chemist and has been in the Industry for 25 years. He joined Adcock in 1994 as a Process Chemist in Research & Development. Kuben was appointed to the Adcock executive team in 2001 as Drug Management & Development Executive. In October 2006, Kuben was appointed to his current position. This position involves a focus on Tenders, ARVs, interaction with various government bodies, industry trade organizations and other pharmaceutical companies on strategic pharmaceutical and policy matters. |
| |
| |
 |
Kennedy Mubaiwa
Medical Executive—Drug Management & Development
MB.ChB; Dip Anaesthesia; MBA
Kennedy Mubaiwa joined Adcock in June 2005 as the Medical Executive responsible for Drug Management and Development. He was previously the Medical Director at Eli Lilly. Kennedy has focused on streamlining the Drug Management and Development capabilities of Adcock in an effort to increase the number and speed of dossier registrations with the MCC. Highlights include the R&D team delivering an ARV portfolio in record time.He has also expanded the capacity to register dossiers in non English speaking African countries. He has assumed responsibility of Group Quality in 2006 refocusing the strategy to drive Adcock towards Pharmaceutical Inspection Cooperation schemes (PIC/s) readiness. |
| |
| |
 |
Viral Desai
NBD Executive
BPharm; BCom
Viral Desai was appointed the New Business Development Executivein September 2005. His experience includes the acquisition of new products, businesses and technology, the negotiating and administering of license agreements with local and international partners, the effective integration of new products within Adcock and development of theHospital Products division five year rolling growth plans. He first joined Adcock in 1999 as a Regulatory Affairs Pharmacist and in May 2002 was appointed as the Regulatory and Clinical Information Manager for the group. In that role he ensured that Adcock had been legally compliant in terms of the Medicines and Related Substances Act and Pharmacy Act regarding product dossiers, promotional material and the duties of a responsible pharmacist.
|
| |
| |
 |
Kym Rowat
Managing Executive Hospital Products
Dip General Nursing; Midwifery, Psychiatry, Intensive Care (Honours), IMM; MBA
Kym Rowat joined the group in 2000, after a 5 year career at 3M, developing sales and marketing competencies and achieving global recognition in 1997 with the 3M Sub Saharan Marketing Award. Since joining the Hospital Products division, Kym has held various roles, including Marketing, Key Accounts, Tenders and Customer Services. In 2002 she became Category Executive for Medicine Delivery and highlights include the consistent growth of the core products through value add proposals, the successful launch of the Infusion pumps to a 54% market share and double digit growth in the new product pipeline with generic injectables. She was appointed Managing Executive of Adcock Ingram Critical Care in January 2008.
|
| |
| |
 |
Shawn Landman
CEO – The Scientific Group
B.Com, B.Acc, CA(SA) – Wits
Shawn Landman joined The Scientific Group in August 2001 as Commercial Director. In October 2005 Adcock Ingram acquired 74% of the shareholding of SG and Shawn was appointed as CEO. He was previously Financial Director of Verimark a specialised FMCG company. Prior to that Shawn held a financial management role within the listed engineering group Dorbyl, which he joined after the completion of his articles with KPMG.
|
| |